SALT
LAKE CITY, Jan. 3, 2024 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that it will be hosting a booth next week at the
2024 Consumer Electronics Show (CES) from January 9-12 in Las
Vegas, Nevada.
The Company will be exhibiting its upcoming Co-Dx™ PCR at-home
and point-of-care platform. Co-Dx recently announced that the Co-Dx
PCR Pro™, along with its Co-Dx PCR COVID-19 test, has been
submitted to the U.S. Food and Drug Administration for Emergency
Use Authorization. Attendees interested in learning more about the
Company, as well as the upcoming product pipeline of tests for the
new platform including tuberculosis, human papillomavirus, and a
respiratory panel for flu A/B, COVID-19 and RSV, are invited
to visit Booth #8925 in the North Hall of the Las Vegas Convention Center.
*The Co-Dx PCR at-home and point-of-care platform (including
the PCR Home™, PCR Pro, mobile app, and all associated test kits)
is subject to review by the FDA and/or other regulatory bodies and
is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR at-home and point-of-care platform and
to locate genetic markers for use in applications other than
infectious disease.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-at-ces-2024-january-9-12-302025073.html
SOURCE Co-Diagnostics